International Biotechnology Trust plc Stock

Equities

IBT

GB0004559349

Investment Trusts

Delayed London S.E. 07:34:03 2024-04-19 am EDT 5-day change 1st Jan Change
611.4 GBX -0.10% Intraday chart for International Biotechnology Trust plc -4.17% -4.77%
Sales 2022 -13.58M -16.92M Sales 2023 10.47M 13.04M Capitalization 253M 315M
Net income 2022 -22M -27.4M Net income 2023 6M 7.47M EV / Sales 2022 -22.5 x
Net Debt 2022 39.98M 49.79M Net Debt 2023 32.47M 40.45M EV / Sales 2023 27.3 x
P/E ratio 2022
-11.9 x
P/E ratio 2023
38.4 x
Employees -
Yield 2022
4.83%
Yield 2023
4.38%
Free-Float 90.88%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : International Biotechnology Trust plc - Special Call
International Biotechnology Trust plc commences an Equity Buyback Plan for 5,851,887 shares, representing 15.05% of its issued share capital, under the authorization approved on December 12, 2023. CI
International Biotechnology Trust plc Elects Gillian Elcock as Director CI
International Biotechnology Trust plc Declares Payment of A First Interim Dividend for the Year Ending 31 August 2023, Payable on 26 January 2024 CI
International Biotechnology Trust plc Approves Dividend Policy CI
International Biotechnology Trust plc's Equity Buyback announced on March 2, 2023, has expired. CI
Origin Enterprises kicks off EUR20 million buyback AN
EARNINGS: Wynnstay "optimistic" despite climate, dotdigital ups profit AN
Earnings Flash (IBT.L) INTL. BIOTECHNOLOGY TRUST Posts FY23 Revenue GBP863,000 MT
International Biotechnology Trust plc Reports Earnings Results for the Full Year Ended August 31, 2023 CI
International Biotechnology Trust Selects Schroders as Fund Manager MT
International Biotechnology Trust plc Declares the Second Interim Dividend for the Period Ending 31 August 2023, Payable on 25 August 2023 CI
Grafenia "cautiously optimistic" about year ahead AN
Earnings Flash (IBT.L) INTL. BIOTECHNOLOGY TRUST Reports H1 EPS GBX41.57 MT
International Biotechnology Trust plc Reports Earnings Results for the Half Year Ended February 28, 2023 CI
More news

Latest transcript on International Biotechnology Trust plc

1 day-0.10%
1 week-4.17%
Current month-6.80%
1 month-5.36%
3 months-2.96%
6 months+1.56%
Current year-4.77%
More quotes
1 week
606.00
Extreme 606
650.00
1 month
606.00
Extreme 606
664.00
Current year
606.00
Extreme 606
704.00
1 year
548.00
Extreme 548
704.00
3 years
548.00
Extreme 548
773.25
5 years
451.00
Extreme 451
862.00
10 years
258.44
Extreme 258.4375
862.00
More quotes
Managers TitleAgeSince
Chief Investment Officer 47 -
Compliance Officer - -
Investor Relations Contact - 15-12-31
Members of the board TitleAgeSince
Chairman 58 20-05-18
Director/Board Member 51 23-01-31
Director/Board Member 59 15-03-31
More insiders
Date Price Change Volume
24-04-19 611.4 -0.10% 12 054
24-04-18 612 -1.45% 41,845
24-04-17 621 -0.96% 47,156
24-04-16 627 -0.63% 101,079
24-04-15 631 -1.10% 63,847

Delayed Quote London S.E., April 19, 2024 at 07:34 am EDT

More quotes
International Biotechnology Trust plc is a United Kingdom-based investment trust company. The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies addressing an unmet medical need. The Company seeks to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have growth prospects, with experienced management and strong potential upside through the development and/or commercialization of a pharmaceutical product, device or enabling technology. The Company’s investments may also be made in related sectors, such as medical devices and healthcare services. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. SV Health Managers LLP is the Company's alternative investment fund manager (AIFM).
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.12
Average target price
-
Consensus

Annual profits - Rate of surprise